Exonate Ltd is a revolutionary biopharmaceutical company that aims to transform the treatment of retinal vascular diseases, such as wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DMO). Utilizing cutting-edge mRNA targeted therapies, Exonate has developed a game-changing eye drop that offers a new approach to treating these conditions. Originally spun out of the University of Nottingham, Exonate has rapidly grown with contributions from the global market.

Their focus lies in regulating Vascular Endothelial Growth Factor (VEGF) isoforms and variants, which play a significant role in both protecting against and promoting retinal diseases. With a strong foundation in scientific excellence and collaborations with top universities, Exonate has formulated small molecules that inhibit the production of pro-angiogenic VEGF, showcasing superior efficacy in preclinical models of wet AMD. Led by a seasoned international management team, Exonate brings together expertise in medicine, finance, drug development, and the pharmaceutical industry.

Backed by notable investors, Exonate is a well-funded business committed to transforming the lives of patients suffering from retinal vascular diseases. Visit their website for more information about their groundbreaking work